Intellia Therapeutics Inc has taken steps to advance its genome editing technology with the acquisition of Rewrite Therapeutics Inc. Intellia will pay Rewrite shareholders $45 million upfront and an additional $155 million and research and regulatory milestones through a mix of Intellia stock and cash. Further financial details were not disclosed.
